Home > Press > Nano-Syringe Delivers Combination, Targeted Brain Cancer Therapy
![]() |
Dr. David Baskin, neurosurgeon, Methodist Neurological Institute Martyn Sharpe, lead author and researcher, Methodist Neurological Institute |
Abstract:
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
Patients with glioblastoma multiforme (GBM), the most common and aggressive malignant primary brain tumor, typically have a prognosis of 14-month median survival time despite medical interventions, which currently include surgery, chemotherapy and radiation.
The Rice-Methodist group developed the hydrophilic carbon cluster (HCC) antibody drug enhancement system (HADES), named after the Greek god of the underworld. Through a 20-nanometer syringe, which is 2 million times smaller than a coffee mug, this nanovector successfully delivered a combination of three chemotherapy drugs into GBM cells in vivo, resulting in a high kill rate.
"Without our nano-delivery system, we know that current drug delivery would be highly toxic to patients if we tried to deliver all three of these drugs at once," said David Baskin, M.D., neurosurgeon at the Methodist Neurological Institute, who began his nanomedicine research in 2004 with the late Nobel laureate and Rice chemist Richard Smalley. "But delivered in combination using these nano-syringes, our research demonstrated extreme lethality, with at least a three-fold increase in the number of dead cancer cells following treatment. The nano-syringes selectively deliver these drugs only to cancer cells, and appear not to be toxic to normal neurons and other non-cancerous brain cells."
HCCs are nanovectors with protective antioxidant properties, capable of transporting and delivering drugs and bioactive molecules. In order to bring the drug carriers close enough to the cancer cells and successfully deliver the chemotherapy combination, three different antibodies were combined with the HCC to allow the nanoparticle to stick to the cell membrane. The drugs stayed inside the HCC until it attached to the cell membrane. Once binding occurred, the drugs were released into the fatty (lipid) environment in the membrane. The chemical properties of the chemotherapy drugs inside the HCC are such that they prefer to accumulate in areas with high concentrations of lipids and avoid areas with high water content, such as the extracellular space.
"A new and exciting advance is that now we have a carrier with protective properties, unlike previous nanotubes which were shown to be toxic," said Martyn Sharpe, the paper's lead author and a scientist with the Methodist NI's department of neurosurgery. "Some of the chemotherapy agents used in this research traditionally perform poorly with GBMs. Now that we've shown a successful kill rate of these cells in vivo, we're looking at treating human tumors that will be grown in immune-compromised mice models."
As personalized medicine continues to evolve, Baskin says this research could also be significant for other forms of cancer, including breast and head and neck cancers.
The paper represents an important collaboration between the laboratories of Baskin at Methodist, and James Tour, Ph.D. with Rice University's Smalley Institute for Nanoscale Science. Further work developing this system and expanding its utility is under way with continued collaboration between these two research groups.
The research was supported by The Henry J. N. Taub Fund for Neurological Research, The Pauline Sterne Wolff Memorial Foundation, Golfers Against Cancer, The Taub Foundation, The Verdant Foundation Limited and The Methodist Hospital Foundation.
For more on the Methodist Neurological Institute, visit us online or call 713-790-3333.
Follow us on Twitter and Facebook.
####
For more information, please click here
Contacts:
Gale Smith
832.667.5843
Copyright © Newswise
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
Nanomedicine
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
Discoveries
Efficient and stable hybrid perovskite-organic light-emitting diodes with external quantum efficiency exceeding 40 per cent July 5th, 2024
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
Announcements
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |